Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Schwerpunktpraxis fuer Gynakologische Onkologie

Research site

Germany Domgasse 1, 15517 Fürstenwalde, Germany

  • 1 trial recruiting
  • Breast cancer female · Hormone receptor positive HER2 negative breast cancer · Breast cancer
  • Adult patients

About Specializations

Schwerpunktpraxis fuer Gynakologische Onkologie in Fürstenwalde, Germany specialises in clinical trials of conditions such as Breast cancer female, Hormone receptor positive HER2 negative breast cancer, Breast cancer, Hormone receptor positive breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Breast Cancer Research

The medical center is at the forefront of breast cancer research, focusing on innovative treatments for node-positive, estrogen receptor-positive, HER2-negative, early breast cancer with a high risk of recurrence. The center's research aims to improve patient outcomes through advanced therapeutic strategies.

  • Invasive Breast Cancer-Free Survival (IBCFS)
  • Endocrine Therapy Innovations
  • Risk Assessment and Management

By evaluating the efficacy of novel treatments such as elacestrant, the center contributes significantly to the development of personalized medicine approaches, enhancing the quality of life and survival rates for patients worldwide.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Domgasse 115517 FürstenwaldeGermany
Open in maps ↗
Recruiting now
1 trial
Conditions studied
12

More sites in FürstenwaldeGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

5 clinical trials

Hormone receptor positive breast cancer+2

Recruiting

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut fuer Frauengesundheit GmbH

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Neoplasm malignant

Not recruiting

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:NSABP Foundation Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.